New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension
Since 2015, macitentan, the new oral dual endothelin receptors antagonist (ERA), has been successfully introduced into clinical practice in the Russian Federation for the treatment of pulmonary arterial hypertension (PAH) patients. It has improved physicochemical properties, which provides tissue sp...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2018-04-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | http://ter-arkhiv.ru/en/archive/2018/vol-90-4-2018/novye-gorizonty-primeneniya-antagonista-retseptorov-endotelina-vtorogo-pokoleniya-matsitentana-u-pats_1460/?element |